Search results
CRISPR Therapeutics’ (CRSP) Neutral Rating Reiterated at Cantor Fitzgerald
ETF DAILY NEWS· 3 days agoCantor Fitzgerald reissued their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Thursday, Benzinga reports ...
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.1% After Analyst Downgrade
ETF DAILY NEWS· 5 days agoCRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) shares dropped 2.1% during trading on Friday after Oppenheimer lowered their price target on the stock from $102.00 ...
Broker Revenue Forecasts For CRISPR Therapeutics AG (NASDAQ:CRSP) Are Surging Higher
Simply Wall St. via Yahoo Finance· 5 days agoCRISPR Therapeutics AG (NASDAQ:CRSP) shareholders will have a reason to smile today, with the...
Wealthcare Advisory Partners LLC Makes New $244,000 Investment in CRISPR Therapeutics AG...
ETF DAILY NEWS· 5 days agoWealthcare Advisory Partners LLC acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the fourth quarter, according to its most recent ...
We're Interested To See How CRISPR Therapeutics (NASDAQ:CRSP) Uses Its Cash Hoard To Grow
Simply Wall St. via Yahoo Finance· 6 days agoNonetheless, only a fool would ignore the risk that a loss making company burns through its cash too...
China fast-tracks edited wheat genome in food security drive
South China Morning Post· 4 days agoKevin Zhao, a co-founder of Qi Biodesign, said the firm had been working with regulators for the...
CRISPR gene editing may help treat rare eye disorder, improve vision
Medical News Today· 7 days agoLCA is a rare genetic eye disorder that normally presents during the first year of life. People with...
Is Bluebird Bio Stock a Buy?
Motley Fool via Yahoo Finance· 1 hour agoCasgevy, another gene-editing treatment for SCD and TDT, earned approval recently. The team of Vertex Pharmaceuticals and CRISPR Therapeutics developed...
Earnings call: Intellia Therapeutics reports robust Q1 progress By Investing.com
Investing.com· 7 days agoIntellia Therapeutics (NASDAQ: NASDAQ:NTLA) has made significant progress in the first quarter of...
CRISPR Therapeutics AG Reports Q1 2024 Earnings: Misses Analyst
Guru Focus· 6 days agoRevenue: Reported at $504K, significantly below the estimated $26.55 million.Net Loss: Totaled $116.59 million, slightly above the estimated loss of $119.19 mi